bioAffinity Technologies to Ring Nasdaq Closing Bell Today
April 05 2023 - 8:00AM
Business Wire
bioAffinity Technologies, Inc. (Nasdaq: BIAF;
BIAFW), a biotechnology company focused on the need for
noninvasive, accurate tests for the detection of early-stage
cancer, will ring the Nasdaq Stock Market closing bell this
afternoon to commemorate the Company’s 2022 initial public offering
(IPO).
“Thank you to Nasdaq for giving us the opportunity to
participate in one of Wall Street’s most time-honored traditions,”
bioAffinity Technologies President and CEO Maria Zannes said. “When
we ring the bell this afternoon, we will be celebrating the many
milestones and scientific discoveries that led to the development
of our first commercial product, CyPath® Lung, which can detect
lung cancer at the earliest stages when treatment options are more
effective and lead to longer, healthier lives.”
The Nasdaq Stock Market closing bell ceremony will run from
approximately 3:45 to 4:05 p.m. Eastern time. A live stream of the
event will be available at
https://livestream.com/accounts/27896496/events/10809033 and
on the Nasdaq Facebook and Twitter pages.
About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a global technology company serving the
capital markets and other industries. Its diverse offering of data,
analytics, software and services enables clients to optimize and
execute their business vision with confidence. To learn more about
the company, technology solutions and career opportunities, visit
Nasdaq on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for
noninvasive diagnosis of early-stage cancer and diseases of the
lung and targeted cancer treatment. The Company’s first product,
CyPath® Lung, is a noninvasive test that has shown high sensitivity
and specificity for the detection of early-stage lung cancer.
CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by
Precision Pathology Services. OncoSelect Therapeutics®, LLC, a
subsidiary of bioAffinity Technologies, is advancing its
discoveries shown in vitro to kill cancer cells without harm to
normal cells. Research and optimization of the Company’s platform
technologies are conducted in its laboratories at The University of
Texas at San Antonio. For more information, visit
www.bioaffinitytech.com and follow us on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements regarding the anticipated use of proceeds from
the Company’s offering of common shares. Forward-looking statements
can be identified by words such as “believes,” “expects,”
“estimates,” “intends,” “may,” “plans,” “will” and similar
expressions, or the negative of these words. Such forward-looking
statements are based on facts and conditions as they exist at the
time such statements are made and predictions as to future facts
and conditions. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230405005222/en/
bioAffinity Technologies Julie Anne Overton Director of
Communications jao@bioaffinitytech.com
LHA Investor Relations Tirth T. Patel tpatel@lhai.com
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Jun 2024 to Jul 2024
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Jul 2023 to Jul 2024